CAR T-Cell Therapy for Relapsed/Refractory CLL
2 Pogledi
• 07/14/23
0
0
Ugraditi
administrator
Pretplatnici
The panelists provide insight on the use of chimeric antigen receptor T-cell therapy for chronic lymphocytic leukemia and the TRANSCEND CLL-004 trial of liso-cel (JCAR017) in relapsed/refractory disease.
Prikaži više
Komentari na Facebooku
SORT BY-
Najbolji komentari
-
Najnoviji komentari